Novartis is one of the world's top pharmaceutical companies, and along with neighbours Roche, the mainstay of Switzerland's centuries-long contribution to new medicines. Headquartered in Basel ...
Pharmaceutical giant Novartis is building a new manufacturing facility in Carlsbad that will help expand the production of ...
Novartis is making two investments in new radiopharmaceutical manufacturing sites in the US. The Swiss pharmaceutical giant will open a third US radioligand plant in Carlsbad, California, to serve the ...
16d
Analyst Etzer Darout of BMO Capital maintained a Hold rating on Novartis (NVS – Research Report), retaining the price target of $118.00.
New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
A separate US-based single-arm OLIKOS Phase IIIb study showed that at 12 months, all clinically stable RMS patients who switched from intravenous (IV) anti-CD20 therapy to Kesimpta showed no new ...
Pharmaceutical Technology on MSN3d
FDA expands Novartis’ Kisqali label to include early breast cancer patientsKisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...
Two of the simplest ways to measure the success of companies that develop and commercialize drugs is to count their approvals ...
Pharmaceutical heavyweights like Bristol Myers Squibb, AstraZeneca, and Eli Lilly are betting big on radiopharmaceuticals, ...
Radioligand therapies (RLTs) have received prominent attention from major pharmaceutical companies in treating prostate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback